Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Picosulfate→

Picosulfate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
10040-34-3
Molecular formula
C18H15NO8S2
Molecular weight
437.4 g/mol
Drug class
Stimulant laxativediphenylmethane derivative activated in the colon
Mechanism of action
Sodium picosulfate is converted by colonic bacteria to the active diphenol metabolite, which stimulates colonic mucosa and enteric nerve plexuses, increasing peristalsis and reducing water absorption. Sodium is a counter-ion, not a separate therapeutic target.
Indications / reported uses
  • Short-term relief of constipation
  • Bowel cleansing before diagnostic or surgical procedures when used in an authorised fixed combination (for example, with magnesium citrate); bowel-preparation indications belong to the specific combination regimen

Sources: UK SmPC — Sodium picosulfate oral preparations · NHS — Picosulfate laxative information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Stimulant laxative; diphenylmethane derivative activated in the colon

Mechanism of action

Sodium picosulfate is converted by colonic bacteria to the active diphenol metabolite, which stimulates colonic mucosa and enteric nerve plexuses, increasing peristalsis and reducing water absorption. Sodium is a counter-ion, not a separate therapeutic target.

General use cases

  • Short-term relief of constipation
  • Bowel cleansing before diagnostic or surgical procedures when used in an authorised fixed combination (for example, with magnesium citrate); bowel-preparation indications belong to the specific combination regimen
Active moiety: picosulfate active moiety (bacterial prodrug) (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

The counter-ion does not create a separate therapeutic API. Picosulfate is converted by colonic bacteria to the active diphenol laxative; bowel preparation versus routine constipation use depends on the product combination and regimen.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Picosulfate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Picosulfate Permitted Daily Exposure (PDE) report (the Picosulfate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Picosulfate Occupational Exposure Limit (OEL) report (the Picosulfate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.